31st mayo 2020
Supporting the surge in COVID-19 clinical trials by assisting recruitment of candidates
Intrepida, a technology company focused on analytics and building artificial intelligence (AI) applications for healthcare challenges is offering access to Ancora.ai, a digital health product for clinical trial search and match, to researchers during the pandemic.
Ancora.ai was designed to connect the surge of new COVID-19 clinical trials to participants. Intrepida invites sponsors of COVID-19 therapeutic, diagnostic and vaccine clinical trials to set up pilots and case studies using Ancora.ai to begin recruiting for critical studies.
Those running COVID-19 clinical trials are faced with the challenge of rapidly recruiting 90,000+ participants, in order to be fully enrolled. Healthcare systems are overwhelmed due to the pandemic and many institutions have little spare time or resource to devote to recruit for, and conduct clinical trials. However, clinical trials represent the most effective way to generate scientific evidence on prospective testing, treatment and prevention strategies to combat the pandemic.
Ancora.ai, a web-based tool that allows for intuitive clinical trial search in recognition of the critical need to support clinical research during this time.
A proprietary, AI-derived questionnaire guides users to answer a few simple questions in order to match to relevant clinical trial options. The tool helps users navigate complex inclusion criteria and the clinical trial enrolment process. Users can save a personal profile, search for trials, view relevant details about the studies, save and share trial listings, connect with trial sites, and view their progress toward enrolment on a personalised dashboard.
Intrepida are welcoming enquiries from sponsors of COVID-19 therapeutic, diagnostic and vaccine clinical trials to set up pilots and case studies.
ASK: Research contributors needed for CON-VICE study
University of Luxembourg needs European researchers to get in touch
OFFER: Funding available for COVID-19 research
Fondation Air Liquide are looking to fund European projects
ASK: Supporting the immunocompromised
Partners sought to advance neutralising antibody